Can a simple blood test tell us when to switch, stop, or add breast cancer treatment?
In Episode 5 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar are joined by Dr. Heather Parsons and patient advocate Julia Maués to explore the evolving role of circulating tumor DNA (ctDNA) in breast cancer treatment decisions.
From SERENA-6 and switching therapy before radiographic progression to HER2CLIMB-05, the STOP-HER2 trial, and AFT-70 NAVIGATE, the conversation examines how ctDNA could help guide treatment escalation, de-escalation, and personalized care.
Beyond the data, they tackle the unanswered questions: When should clinicians act on molecular findings? Can some patients safely stop treatment? And how do we balance promising innovations with treatment burden, toxicity, and patient preferences?
▶️ Watch on YouTube - https://youtu.be/Mh2uNBGrRLI
🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio: https://linkin.bio/cancerunfiltered
Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.
#CancerUnfiltered #ctDNA #BreastCancer #SERENA6 #STOPHER2 #NAVIGATETrial #MetastaticBreastCancer #PrecisionOncology #MedicalOncology #CommunityHealthMedia
